Matrix Capital Management led the immunology drug developer's series A round, which will support the journey of a type 1 diabetes drug candidate towards the clinic.

GentiBio, a US-based developer of immunology therapies based on findings from several research centres, has completed a $157m series A round led by investment manager Matrix Capital Management.
The round included pharmaceutical firm Novartis, which invested through its Novartis Venture Fund, as well as Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management and Seattle Children’s Research Institute.
GentiBio is engineering specialised regulatory T cells (Tregs) that will form the basis of therapeutics for autoimmune, alloimmune, autoinflammatory and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
email
Linked in